OCULUS INNOVATIVE SCIENCES RECEIVES FDA CLEARANCE FOR OVER-THE-COUNTER MARKETING OF DERMACYN™ WOUND CARE

Formulated with patented Microcyn® Technology-- Non-Toxic and Stable Super-Oxidized Water

PETALUMA, CA-- (March 8, 2006)— Hoji Alimi, president and CEO of Oculus Innovative Sciences, today announced that the U.S. Food and Drug Administration has granted clearance to market a consumer-specific version of Dermacyn™ Wound Care as an over-the-counter (OTC) product in the United States. The FDA approved the company’s OTC product with more limited label claims than Oculus’ prescription Dermacyn™ formula.

The company’s first domestic wound care product, Dermacyn™ Wound Care, received two FDA 510(k) clearances in May 2005, and is available in the United States by prescription only. It is used for moistening absorbent wound dressings and for debriding and cleaning acute and chronic dermal lesions, such as Stage I-IV pressure ulcers, stasis ulcers, diabetic ulcers, post-surgical wounds, first- and second-degree burns, abrasions and minor irritations of the skin.

The new consumer brand, Dermacyn™ Wound Care OTC, is intended for general-purpose use, including moistening of absorbent wound dressing and cleaning minor and superficial skin abrasions. The company expects Dermacyn™ Wound Care OTC to be available for purchase without prescription as early as April 2006.

Consumers will be able to purchase Dermacyn™ Wound Care OTC by phoning 1-800-759-9305 or visiting the company’s on-line store at http://store.oculusis.com.

About Oculus
Oculus Innovative Sciences is a medical technology company focused on the development, manufacture and marketing of Microcyn® Technology. Microcyn®-based products are currently being used in the treatment of both chronic and acute wounds in the European Union, United States, Mexico and Southeast Asia. The Microcyn™ Technology received CE approval according to the European Medical Devices Directive (93/42/EEC) for Dermacyn™ Wound Care in November 2004. It also received two FDA 510K clearances in May 2005 to be marketed under the brand name of Dermacyn™ Wound Care in the United States as a medical device to lubricate, moisten, cleanse and debride wounds and burns.

Oculus’ principal operations are in Petaluma, California, and it conducts operations in Europe and Latin America through its wholly owned subsidiaries, Oculus Innovative Sciences Netherlands B.V. and Oculus Technologies of Mexico, S.A. de C.V. Visit the website at:www.oculusis.com.

(Download PDF: 112 KB)